GSK receives positive opinion for triple-therapy inhaler

03:58 EDT 15 Sep 2017 | Pharmafile

GSK, alongside its partner Innoviva, has announced that it has received a positive opinion from the EMA’s CHMP for its Trelegy Ellipta treatment for chronic obstructive pulmonary disease (COPD).

The inhaler combines fluticasone furoate, umeclidinium and vilanterol as part of maintenance treatment for the condition in those who do not respond suitably to a combination of an inhaled corticosteroid and a long-acting beta2-agonist.

read more

Original Article: GSK receives positive opinion for triple-therapy inhaler


More From BioPortfolio on "GSK receives positive opinion for triple-therapy inhaler"

Quick Search

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...